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management of patients with chronic hepatitis
C and alcoholic liver diseaseTable 1 Characteristics of patients with alcoholic
cirrhosis who survived versus deceased.
Variables Survival Nonsurvival p
No. 61 22
Age (y) 46  10 47  11 0.68
Male sex 55 (90) 20 (91) 0.92
Hepatic encephalopathy 9 (15) 6 (27) 0.19
Ascites 26 (43) 11 (50) 0.55
Esophageal varices 35 (57) 14 (64) 0.61
Esophageal variceal bleeding 1 (2) 3 (14) 0.02
Data are presented as mean  SD or n (%).
SDZ standard deviation.To the Editor,
I read with great interest the article by Lin et al1 on the
effect of alcohol and racial difference on the treatment
outcome of hepatitis C virus infection. I strongly agree that
the major contributing factor to the response rate of
interferon therapy is compliance, especially among
drinkers, and that a multidisciplinary approach is effective
to optimize the treatment response. In this study, the au-
thors employed a reference nurse who made regular visits
and successfully raised the sustained virological response
rate among drinkers. Was there a significant overlap be-
tween drinkers and Aboriginal people? How did the two
factors, i.e., drinkers and Aboriginal people, interact in
relation to treatment effects?
More than 10 years ago, we initiated a multidisciplinary
approach that included nurse interview on treatment side
effects and rating depression scale during outpatient visits.
This approach substantially improved the acceptance and
compliance rate to interferon therapy. Factors that corre-
late with compliance include recent alcohol use and
depression.2 On the adverse events of pegylated interferon
and ribavirin therapy in chronic hepatitis C patients, we
found that depression developed early in the course of
therapy3; thus, a multidisciplinary approach should be
started early, even before the treatment is initiated. In this
study, was there a difference in the rate of treatment side
effects between drinkers or not, and among different races?
We also applied the same multidisciplinary approach to
the management of patients with alcoholic liver disease,
including the assessment of depression scale and consulta-
tion with a psychiatrist. Active multidisciplinary assessment
leads to better patient outcome.4 In the analysis of 83 pa-
tients with alcoholic cirrhosis undergoing multidisciplinaryConflicts of interest: The author has no conflicts of interest
relevant to this article.
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less complications than their nonsurviving counterparts
(Table 1). It is our practice to implement the multidisci-
plinary approach not only for chronic hepatitis C drinkers
undergoing pegylated interferon therapy, but also for those
with alcoholic liver disease.References
1. Lin CC, Wu CH, Chen HL, Lin IT, Chen MJ, Wang TE, et al.
Hepatitis C treatment outcome in relation to alcohol con-
sumption and racial differences in southeastern Taiwan. J For-
mos Med Assoc 2015;114:1069e75.
2. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al.
Depression, anemia and health-related quality of life in chronic
hepatitis C. J Hepatol 2006;44:491e8.
3. Huang YW, Hu JT, Hu FC, Chang CJ, Chang HY, Kao JH, et al.
Biphasic pattern of depression and its predictors during pegy-
lated interferon-based therapy in chronic hepatitis B and C
patients. Antivir Ther 2013;18:567e73.by Elsevier Taiwan LLC. This is an open access article under the CC
).
1098 Letter to the Editor4. Huang YW, Hu JT, Yang SS. Complications of alcoholic liver
cirrhosis: active assessment by endoscopy and sonography.
Hepatology 2010;52:1864e5.
Yi-Wen Huang*
Liver Center, Cathay General Hospital Medical Center,
Taipei, Taiwan
School of Medicine, Taipei Medical University College of
Medicine, Taipei, Taiwan
School of Medicine, China Medical University, Taichung,
TaiwanDivision of Gastroenterology, Department of Internal
Medicine, National Taiwan University College of Medicine,
Taipei, Taiwan*Corresponding author. Liver Center and Health Manage-
ment Center, Cathay General Hospital Medical Center,
Number 280, Section 4, Jen-Ai Road, Taipei 10630, Taiwan.
E-mail address: yiwenhuang@ntu.edu.tw
28 September 2016
